DMG PEG2000 DBCO Conjugate

DMG PEG2000 DBCO Conjugate Catalog B2013236 (5 mg)

DMG PEG2000 DBCO Conjugate is a highly specialized lipidpolymerclick chemistry reagent combining a dimyristoyl glycerol lipid anchor, a polyethylene glycol (2000 Da) spacer, and a DBCO functional group for bio-orthogonal labeling. Supplied as a purified solution (Catalog B2013236, 5 mg), this conjugate is ideal for integrating lipid membranes with click-ready surfaces, supporting click-based conjugation protocols in nanocarrier design, biomolecule functionalization, or targeted delivery systems.

Engineered with biotech-grade purity and ultrapure filtration, DMG PEG2000 DBCO ensures uniform integration and reliable performance in conjugation workflow pipelines. The PEG spacer enhances solubility and reduces nonspecific interactions, while the DBCO group enables strain-promoted click reactions with azide-functionalized partners under mild conditionscritical for maintaining biomolecular integrity. It supports imaging, targeting, and assay development across biotech and biochemical research. The product is stored at 20 C, ensuring long-term stability and batch-to-batch reproducibility. Custom bulk orders are available to support high-throughput or translational projects.

Why researchers choose this product:

• Lipid anchor (DMG) provides seamless membrane integration.
• PEG(2000) spacer offers stealth, solubility, and reduced aggregation.
• DBCO group allows efficient strain-promoted click chemistry with azide-bearing molecules.
• High purity supports precise conjugation and minimal background noise.
• Available in bulk for scalable assay development or high-throughput studies.

Indication for Use:
This product is for Research Use Only (RUO). It is not intended for diagnostic, therapeutic, or clinical use.

References:

• 1: Wei Y, Luo L, Gui T, Yu F, Yan L, Yao L, Zhong L, Yu W, Han B, Patel JM, Liu JF, Beier F, Levin LS, Nelson C, Shao Z, Han L, Mauck RL, Tsourkas A, Ahn J, Cheng Z, Qin L. Targeting cartilage EGFR pathway for osteoarthritis treatment. Sci Transl Med. 2021 Jan 13;13(576):eabb3946.
• 2: Qian R, Jing B, Jiang D, Gai Y, Zhu Z, Huang X, Gao Y, Lan X, An R. Multi-antitumor therapy and synchronous imaging monitoring based on exosome. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2668-2681.
• 3: Wang H, Sobral MC, Zhang DKY, Cartwright AN, Li AW, Dellacherie MO, Tringides CM, Koshy ST, Wucherpfennig KW, Mooney DJ. Metabolic labeling and targeted modulation of dendritic cells. Nat Mater. 2020 Nov;19(11):1244-1252.
• 4: Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis. J Clin Pharmacol. 2020 Jan;60(1):37-49.
• 5: Zhang C, Dai P, Vinogradov AA, Gates ZP, Pentelute BL. Site-Selective Cysteine-Cyclooctyne Conjugation. Angew Chem Int Ed Engl. 2018 May 28;57(22):6459-6463.
• 6: Klein PM, Wagner E. Click-Shielded and Targeted Lipopolyplexes. Methods Mol Biol. 2019;2036:141-164.
• 7: Lyu M, Yazdi M, Lin Y, Hhn M, Lchelt U, Wagner E. Receptor-Targeted Dual pH-Triggered Intracellular Protein Transfer. ACS Biomater Sci Eng. 2022 Jul 8.
• 8: Xu X, Liu L, Wang H, Li W, Zou Y, Zeng Y, Yang Q, Bai D, Dai D. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomater Sci Eng. 2022 Nov 14;8(11):4819-4826.
• 9: Vespa S, Del Biondo P, Simeone P, Cavallucci I, Catitti G, Auciello R, De Bellis L, Altomare I, Pieragostino D, Santilli F, Urbani A, De Laurenzi V, Stuppia L, Lanuti P. Basophil Activation Test with Different Polyethylene Glycols in Patients with Suspected PEG Hypersensitivity Reactions. Int J Mol Sci. 2022 Nov 23;23(23):14592.
• 10: Sales ZS, Mani N, Herrmann AT. Practical syntheses of DOTAGA-DBCO and DFO-DBCO, strained alkyne pre-precursors to radioimmunoconjugates for targeted alpha therapy. Bioorg Med Chem. 2022 Nov 1;73:117010.